Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
AAPS J ; 25(5): 89, 2023 09 15.
Artigo em Inglês | MEDLINE | ID: mdl-37715073

RESUMO

Qualifying critical reagents in ligand binding assays by parallel testing of current and candidate reagent lots is recommended by regulatory agencies and industry groups, but specific guidance on the format of reagent qualification experiments is limited. Equivalence testing is a statistically sound approach that is consistent with the objective of critical reagent qualification. We present power analysis for equivalence regions ranging from 1.25- to 1.5-fold multiples of the GM ratio (centered on 1) of current and candidate lots, over a range of assay variability from 5 to 30% coefficient of variation (CV). A 1.25-fold equivalence region can be tested using 6 to 12 plates per lot for assays with up to 15% CV but is not practical for more variable assays. For these assays, wider equivalence regions are justified so long as care is taken to avoid assay drift and the assay remains suitable for the intended use. The equivalence test method is illustrated using historical data from passing and failing reagent qualification experiments. Simulation analysis was performed to support the design of qualification experiments using 6, 12, or 18 plates per lot over a broad range of assay variability. A challenge in implementing the equivalence test approach is selecting an appropriate equivalence region. Equivalence regions providing 90% power using 12 plates/lot were consistent with 1.5σ bounds, which are recommended for equivalence testing of critical quality attributes of biosimilars.


Assuntos
Medicamentos Biossimilares , Ligantes , Bioensaio , Simulação por Computador
2.
Antibiotics (Basel) ; 12(8)2023 Aug 19.
Artigo em Inglês | MEDLINE | ID: mdl-37627757

RESUMO

Francisella tularensis subspecies tularensis is a category-A biothreat agent that can cause lethal tularemia. Ceftobiprole medocaril is being explored as a medical countermeasure for the treatment of pneumonic tularemia. The efficacy of ceftobiprole medocaril against inhalational tularemia was evaluated in the Fischer 344 rat model of infection. The dose was expected to be effective against F. tularensis isolates with ceftobiprole minimum inhibitory concentrations ≤0.5 µg/mL. Animals treated with ceftobiprole medocaril exhibited a 92% survival rate 31 days post-challenge, identical to the survival of levofloxacin-treated rats. By comparison, rats receiving placebo experienced 100% mortality. Terminally collected blood, liver, lung, and spleen samples confirmed disseminated F. tularensis infections in most animals that died prior to completing treatments (placebo animals and a rat treated with ceftobiprole medocaril), although levels of bacteria detected in the placebo samples were significantly elevated compared to the ceftobiprole-medocaril-treated group geometric mean. Furthermore, no evidence of infection was detected in any rat that completed ceftobiprole medocaril or levofloxacin treatment and survived to the end of the post-treatment observation period. Overall, survival rates, body weights, and bacterial burdens consistently demonstrated that treatment with ceftobiprole medocaril is efficacious against otherwise fatal cases of pneumonic tularemia in the rat model.

3.
Exp Clin Psychopharmacol ; 31(3): 733-744, 2023 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-36174143

RESUMO

Alcohol and tobacco use are interrelated. This study examined response to very low nicotine content (VLNC) and moderate nicotine content (MNC) cigarettes by problematic drinking. We utilized a double-blind, randomized, within-subjects crossover design of VLNC and MNC cigarettes in two groups of adult cigarette smokers: with at-risk drinking (ARD; n = 23) and without ARD (n = 24). Participants smoked only their assigned experimental cigarette in their home environment for 7 days, and completed laboratory visits, including ad libitum smoking of the assigned experimental cigarette, at the beginning and end of each experimental week. Participants smoked their usual cigarettes for 7 days between conditions. Participants provided daily reports of alcohol and cigarette consumption. Current Diagnostic and Statistical Manual of Mental Disorders-5th edition (DSM-5) alcohol use disorder (AUD) was assessed at baseline and the end of each experimental week. Compliance with smoking of experimental cigarettes was good. Adjusting for baseline drinking, there was no significant effect of experimental cigarette or ARD group on drinks per day or alcohol urges. There was no effect of experimental cigarette or ARD group on cigarettes per day, or on any puff topography outcome or postsmoking exhaled carbon monoxide during laboratory smoking. No participant had a change in AUD status or AUD severity. After 7 days of exposure to VLNC cigarettes, adult cigarette smokers with ARD did not show compensatory drinking or compensatory smoking behavior. A future policy change in the United States to reduce nicotine content in cigarettes may not produce unintended compensatory drinking or smoking among this vulnerable and prevalent population of smokers. (PsycInfo Database Record (c) 2023 APA, all rights reserved).


Assuntos
Abandono do Hábito de Fumar , Produtos do Tabaco , Adulto , Humanos , Consumo de Bebidas Alcoólicas/epidemiologia , Etanol , Nicotina , Fumaça , Fumantes , Fumar/epidemiologia , Nicotiana , Estudos Cross-Over , Método Duplo-Cego
4.
Vaccines (Basel) ; 10(8)2022 Aug 18.
Artigo em Inglês | MEDLINE | ID: mdl-36016226

RESUMO

Non-human primate (NHP) efficacy data for several Ebola virus (EBOV) vaccine candidates exist, but definitive correlates of protection (CoP) have not been demonstrated, although antibodies to the filovirus glycoprotein (GP) antigen and other immunological endpoints have been proposed as potential CoPs. Accordingly, studies that could elucidate biomarker(s) that statistically correlate, whether mechanistically or not, with protection are warranted. The primary objective of this study was to evaluate potential CoP for Novavax EBOV GP vaccine candidate administered at different doses to cynomolgus macaques using the combined data from two separate, related studies containing a total of 44 cynomolgus macaques. Neutralizing antibodies measured by pseudovirion neutralization assay (PsVNA) and anti-GP IgG binding antibodies were evaluated as potential CoP using logistic regression models. The predictive ability of these models was assessed using the area under the receiver operating characteristic (ROC) curve (AUC). Fitted models indicated a statistically significant relationship between survival and log base 10 (log10) transformed anti-GP IgG antibodies, with good predictive ability of the model. Neither (log10 transformed) PsVNT50 nor PsVNT80 titers were statistically significant predictors of survival, though predictive ability of both models was good. Predictive ability was not statistically different between any pair of models. Models that included immunization dose in addition to anti-GP IgG antibodies failed to detect statistically significant effects of immunization dose. These results support anti-GP IgG antibodies as a correlate of protection. Total assay variabilities and geometric coefficients of variation (GCVs) based on the study data appeared to be greater for both PsVNA readouts, suggesting the increased assay variability may account for non-significant model results for PsVNA despite the good predictive ability of the models. The statistical approach to evaluating CoP for this EBOV vaccine may prove useful for advancing research for Sudan virus (SUDV) and Marburg virus (MARV) candidate vaccines.

5.
PLoS One ; 16(7): e0252874, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34214118

RESUMO

Filoviruses (Family Filoviridae genera Ebolavirus and Marburgvirus) are negative-stranded RNA viruses that cause severe health effects in humans and non-human primates, including death. Except in outbreak settings, vaccines and other medical countermeasures against Ebola virus (EBOV) will require testing under the FDA Animal Rule. Multiple vaccine candidates have been evaluated using cynomolgus monkeys (CM) exposed to EBOV Kikwit strain. To the best of our knowledge, however, animal model development data supporting the use of CM in vaccine research have not been submitted to the FDA. This study describes a large CM database (122 CM, 62 female and 60 male, age 2 to 9 years) and demonstrates the consistency of the CM model through time to death models and descriptive statistics. CMs were exposed to EBOV doses of 0.1 to 100,000 PFU in 33 studies conducted at three Animal Biosafety Level 4 facilities, by three exposure routes. Time to death was modeled using Cox proportional hazards models with a frailty term that incorporated study-to-study variability. Despite significant differences attributed to exposure variables, all CMs exposed to the 100 to 1,000 pfu doses commonly used in vaccine studies died or met euthanasia criteria within 21 days of exposure, median 7 days, 93% between 5 and 12 days of exposure. Moderate clinical signs were observed 4 to 5 days after exposure and preceded death or euthanasia by approximately one day. Viremia was detected within a few days of infection. Hematology indices were indicative of viremia and the propensity for hemorrhage with progression of Ebola viremia. Changes associated with coagulation parameters and platelets were consistent with coagulation disruption. Changes in leukocyte profiles were indicative of an acute inflammatory response. Increased liver enzymes were observed shortly after exposure. Taken together, these factors suggest that the cynomolgus monkey is a reliable animal model for human disease.


Assuntos
Ebolavirus/fisiologia , Doença pelo Vírus Ebola , Animais , Modelos Animais de Doenças , Surtos de Doenças , Feminino , Macaca fascicularis , Masculino , Reprodutibilidade dos Testes , Carga Viral
6.
Birth Defects Res ; 112(16): 1260-1272, 2020 10.
Artigo em Inglês | MEDLINE | ID: mdl-32735073

RESUMO

BACKGROUND: In developmental and reproductive toxicity studies, analysis of litter-based binary endpoints (e.g., incidence of malformed fetuses) is complex in that littermates often are not entirely independent of one another. It is well established that the litter, not the individual fetus, is the proper independent experimental unit in statistical analysis. Accordingly, analysis is often based on the proportion affected per litter and the litter proportions are analyzed as continuous data. Because these proportional data generally do not meet assumptions of symmetry or normality, data are typically analyzed by nonparametric methods, arcsine square root transformation, or logit transformation. METHODS: We conducted power calculations to compare different approaches (nonparametric, arcsine square root-transformed, logit-transformed, untransformed) for analyzing litter-based proportional data. A reproductive toxicity study with a control and one treated group provided data for two endpoints: prenatal loss, and fertility by in utero insemination (IUI). Type 1 error and power were estimated by 10,000 simulations based on two-sample one-tailed t tests with varying numbers of litters per group. To further compare the different approaches, we conducted additional analyses with shifted mean proportions to produce illustrative scenarios. RESULTS: Analyses based on logit-transformed proportions had greater power than those based on untransformed or arcsine square root-transformed proportions, or nonparametric procedures. CONCLUSION: The logit transformation is preferred to the other approaches considered when making inferences concerning litter-based proportional endpoints, particularly with skewed distributions. The improved performance of the logit transformation becomes increasingly pronounced as the response proportions are increasingly close to the boundaries of the parameter space.


Assuntos
Reprodução , Projetos de Pesquisa , Feminino , Humanos , Incidência , Gravidez
7.
Vaccine ; 37(43): 6356-6361, 2019 10 08.
Artigo em Inglês | MEDLINE | ID: mdl-31530467

RESUMO

The anthrax vaccine candidate AV7909 is being developed as a next-generation vaccine for a post-exposure prophylaxis (PEP) indication against anthrax. AV7909 consists of the anthrax vaccine adsorbed (AVA) (Emergent BioSolutions Inc., Lansing, MI) bulk drug substance adjuvanted with the immunostimulatory oligodeoxynucleotide (ODN) compound, CPG 7909. The addition of CPG 7909 to AVA enhances both the magnitude and the kinetics of antibody responses in animals and human subjects, making AV7909 a suitable next-generation vaccine for use in a PEP setting. Emergent has produced a thermostable (lyophilized) formulation of AV7909 vaccine utilizing drying technology. The purpose of the study described here was to assess the immunogenicity and efficacy of the lyophilized formulation of the AV7909 vaccine candidate as compared with the liquid formulation in the guinea pig general-use prophylaxis (GUP) model. The study also provides initial information on the relationship between the immune response induced by the thermostable formulation of the vaccine, as measured by the toxin neutralization assay (TNA), and animal survival following lethal anthrax aerosol challenge. Results demonstrated that there were no significant differences in the immunogenicity or efficacy of lyophilized AV7909 against lethal anthrax spore aerosol challenge in the guinea pig model as compared to liquid AV7909. For both vaccine formulations, logistic regression modeling showed that the probability of survival increased as the pre-challenge antibody levels increased.


Assuntos
Vacinas contra Antraz/química , Vacinas contra Antraz/imunologia , Anticorpos Antibacterianos/sangue , Imunogenicidade da Vacina , Temperatura , Adjuvantes Imunológicos , Animais , Antraz/prevenção & controle , Anticorpos Neutralizantes/sangue , Antígenos de Bactérias/imunologia , Feminino , Liofilização , Cobaias , Masculino , Oligodesoxirribonucleotídeos/imunologia , Profilaxia Pós-Exposição , Vacinação , Potência de Vacina
8.
Anal Chem ; 88(14): 7068-75, 2016 07 19.
Artigo em Inglês | MEDLINE | ID: mdl-27295356

RESUMO

In this proof of concept study, chemical threat agent (CTA) samples were classified to their sources with accuracies of 87-100% by applying a random forest statistical pattern recognition technique to analytical data acquired by comprehensive two-dimensional gas chromatography with time-of-flight mass spectrometric detection (GC × GC-TOFMS). Three organophosphate pesticides, chlorpyrifos, dichlorvos, and dicrotophos, were used as the model CTAs, with data collected for 4-6 sources per CTA and 7-10 replicate analyses per source. The analytical data were also evaluated to determine tentatively identified chemical attribution signatures for the CTAs by comparing samples from different sources according to either the presence/absence of peaks or the relative responses of peaks. These results demonstrate that GC × GC-TOFMS analysis in combination with a random forest technique can be useful in sample classification and signature identification for pesticides. Furthermore, the results suggest that this combination of analytical chemistry and statistical approaches can be applied to forensic analysis of other chemicals for similar purposes.


Assuntos
Compostos Organofosforados/análise , Praguicidas/análise , Clorpirifos/análise , Clorpirifos/classificação , Cromatografia Gasosa/métodos , Diclorvós/análise , Diclorvós/classificação , Cromatografia Gasosa-Espectrometria de Massas/métodos , Modelos Estatísticos , Compostos Organofosforados/classificação , Praguicidas/classificação
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...